Drug Profile
MTL 003
Alternative Names: MTL-003Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Morvus Technology
- Class Antineoplastics; Proteins
- Mechanism of Action Angiogenesis inhibitors; Endothelial cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in United Kingdom
- 13 Jul 2016 Early research in Cancer in United Kingdom (unspecified route)